Shikari® (S-ATV) Anti-Vedolizumab ELISA
VED-QLS-ENT
Enzyme immunoassay for the qualitative determination of specific antibodies to Vedolizumab (Entyvio®) in human serum and plasma.
This kit has been especially developed for the qualitative determination of vedolizumab in serum and plasma samples.
The Matriks Biotek Antibody to Vedolizumab ELISA Kit can be efficiently used for monitoring anti-Vedolizumab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-Vedolizumab antibodies. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.
For technical inquiry, please contact techsupport@matriksbiotek.com
| Required Volume (µl) | 20 |
| Total Time (min) | 140 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | + / - |
| Spike Recovery (%) | - |
| Shelf Life (year) | 1 |
| Assay type | Qualitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
| # | File | Action |
|---|---|---|
| Instructions For Use | Download | |
| Safety Data Sheet (SDS) | Download |
Publications with this drug
| # | File | Action |
|---|---|---|
| Cusato, Jessica, et al. "Therapeutic Drug Monitoring as a Tool for the Clinical Outcome Prediction in Vedolizumab-Treated Patients: An Italian Pilot Study." Biomedicines 12.4 (2024): 824. | Download |
